Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.52 |
| ▸ | ACLY | P53396 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
| ▸ | PTPRB | P23467 | 1/20 | 0.42 |
| ▸ | CDC25A | P30304 | 1/20 | 0.42 |
| ▸ | CDC25B | P30305 | 1/20 | 0.42 |
| ▸ | PTEN | P60484 | 1/20 | 0.42 |
| ▸ | PTPMT1 | Q8WUK0 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL316406 | 0.87 | SMN1; SMN2 (0.55) | FFAR1ACLYRXRARXRBRXRG | |
| SCHEMBL3930469 | 0.86 | FFAR4 (0.47) | KEAP1FFAR1ACLYFFAR4GPR17 | |
| SCHEMBL22088079 | 0.86 | FFAR1 (0.49) | KEAP1FFAR1ACLYFFAR4NPSR1 | |
| SCHEMBL34471236 | 0.86 | FFAR1 (0.46) | KEAP1FFAR1ACLYFFAR4GPR17 | |
| SCHEMBL29197998 | 0.85 | MAPT (0.55) | — | |
| SCHEMBL17310946 | 0.83 | RXRA (0.51) | FFAR1FFAR4GPR17RXRARXRB | |
| SCHEMBL5670212 | 0.83 | KEAP1 (0.64) | KEAP1FFAR1FFAR4NPSR1RXRA | |
| SCHEMBL21098761 | 0.82 | FFAR4 (0.51) | FFAR1FFAR4 | |
| SCHEMBL1845436 | 0.81 | FFAR1 (0.65) | KEAP1FFAR1FFAR4RXRARXRB | |
| SCHEMBL3591978 | 0.81 | ACLY (0.37) | KEAP1FFAR1ACLYFFAR4GPR17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117143097-A | Beta-carbopol compound, preparation method thereof and application of beta-carbopol compound in resisting Alzheimer disease | 中国人民解放军北部战区总医院 | 2023-12-01 | — | — | CN | claimed |
| EP-0553107-A1 | PROTEIN KINASE C MODULATORS WITH ANTI-INFLAMMATORY AND ANTIVIRAL ACTIVITY | PROCYON PHARMACEUTICALS, INC. (US) | 1993-08-04 | — | — | EP | claimed |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2025011610-A1 | AMIDE DERIVATIVE, AND COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-01-16 | — | — | WO | disclosed |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2024-08-15 | — | — | US | disclosed |
| EP-3470407-B1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-4298105-A1 | COMPOUNDS USEFUL IN HIV TREATMENT | VIIV Healthcare Company (US) | 2024-01-03 | — | — | EP | disclosed |
| CN-117143097-A | Beta-carbopol compound, preparation method thereof and application of beta-carbopol compound in resisting Alzheimer disease | 中国人民解放军北部战区总医院 | 2023-12-01 | — | — | CN | disclosed |
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| EP-0125033-B1 | DOPAMINE-BETA-HYDROXYLASE INHIBITORS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-04-26 | — | — | EP | disclosed |
| EP-0308573-A2 | Intermediates useful in the preparation of dopamine-beta-hydroxylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1989-03-29 | — | — | EP | disclosed |
| US-4810811-A | CHEMICAL INTERMEDIATES | SMITHKLINE BECKMAN CORPORATION (US) | 1989-03-07 | — | — | US | disclosed |
| EP-0288488-A1 | DOPAMINE- -HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1988-11-02 | — | — | EP | disclosed |
| WO-1988001267-A1 | DOPAMINE-ss-HYDROXYLASE INHIBITORS | SMITHKLINE BECKMAN CORPORATION (US) | 1988-02-25 | — | — | WO | disclosed |
| US-4707488-A | HYPOTENSIVE AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1987-11-17 | — | — | US | disclosed |
| EP-0212066-A1 | Intermediates useful in the preparation of dopamine-beta-hydroxylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1987-03-04 | — | — | EP | disclosed |
| EP-0191621-A2 | Dopamine-bêta-hydroxylase inhibitors | SMITHKLINE BECKMAN CORPORATION (US) | 1986-08-20 | — | — | EP | disclosed |
| EP-0125033-A1 | Dopamine-beta-hydroxylase inhibitors | SMITHKLINE BECKMAN CORPORATION (US) | 1984-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | KEAP1 1361/4885FFAR1 3654/4885ACLY 2496/4885 |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | KEAP1 489/4885FFAR1 4857/4885ACLY 1052/4885 |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | KEAP1 489/4885FFAR1 4857/4885ACLY 1052/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | KEAP1 420/4885FFAR1 4825/4885ACLY 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.